PhaseBio drops pemziviptadil program in COVID-19

26 October 2020

Cardiopulmonary diseases focussed US firm PhaseBio Pharmaceuticals (Nasdaq: PHAS) on Friday announced that, after a strategic review of the VANGARD clinical trial of its investigational drug pemziviptadil that included an assessment of the evolving COVID-19 treatment landscape, feedback from the US Food and Drug Administration and an interim analysis of the VANGARD study data, it has elected to discontinue the trial.

Importantly, pemziviptadil was generally well tolerated and there was no adverse safety signal reported in the VANGARD trial, said the company, whose shares nevertheless fell 8.5% to $3.20 by close of trading.

In response to the medical community’s rapidly evolving understanding of COVID-19 disease progression and approaches to treatment, PhaseBio recently submitted a revised VANGARD trial protocol and received feedback from the FDA regarding the regulatory and development path in COVID-related ARDS.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK